Welcome to our dedicated page for Genvor news (Ticker: GNVR), a resource for investors and traders seeking the latest updates and insights on Genvor stock.
Genvor Inc (GNVR) drives innovation in agricultural biotechnology through patented peptide solutions and strategic USDA research partnerships. This dedicated news hub delivers official updates on corporate developments, financial milestones, and scientific advancements in sustainable crop protection.
Access verified information on GNVR's progress in biological foliar applications and transgenic seed technologies. Our curated news collection covers essential updates including earnings reports, product launches, institutional collaborations, and peer-reviewed research findings across key crops like corn, citrus, and rice.
Stay informed about critical developments in aflatoxin mitigation strategies and licensing agreements that shape agricultural markets. This resource serves investors and industry professionals seeking comprehensive insights into GNVR's market position and technological roadmap.
Bookmark this page for direct access to Genvor's latest press releases and regulatory filings. Regular updates ensure timely awareness of developments impacting sustainable agriculture and plant health innovation.
Genvor (OTCQB: GNVR) announced the USPTO issued U.S. Patent No. 12,458,684 on Nov 12, 2025 for “Transgenic Corn with Antifungal Peptide AGM182,” co‑assigned to Genvor and the USDA. The patent covers transgenic corn expressing AGM182 designed to reduce fungal infections and mycotoxin accumulation, including activity shown against Aspergillus flavus and Fusarium species.
Published results cited in Plant Science and Plant Disease report 76–98% reduction in total aflatoxin contamination, no adverse plant growth or yield effects, and no observed mammalian toxicity. The company highlights potential foliar spray and transgenic seed applications to address multi‑billion dollar U.S. corn losses from fungal diseases.
Genvor (OTCID: GNVR) regained active OTCQB trading status on October 9, 2025, positioning the company to accelerate capital formation as it scales field trials and commercialization efforts.
The company said it now operates a newly opened laboratory in Woodland, California to support R&D for foliar and peptide-based formulations, and it is advancing four international research collaborations across Europe, Brazil, and the United States focused on peptide-based seed traits and foliar applications.
Management highlighted that these developments support product validation, global field trials, and expanded scientific capabilities for sustainable agriculture.
FAQ
What is the current stock price of Genvor (GNVR)?
What is the market cap of Genvor (GNVR)?
